Abivax S.A.
ABVX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001956827
No open-market purchases or sales by Abivax S.A. insiders were filed in the last 90 days; 318 institutions reported holding it in 13F filings for Q3 2026, worth $5.64B in total; no superinvestor holds it.
Other share classesAAVXF
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +15 vs. previous quarter
- 318
- 13F valueReported value at the end of Q3 2026
- $5.64B
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in EUR.
- Revenue, FY2025
- EUR 4.57M
- −63.3% year over year
- Net income, FY2025
- EUR -336.1M
- No comparable prior period
- Free cash flow, FY2025
- EUR -161.3M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: EUR 336.1M (7354.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 4.11M
- Shares sold short
- Change
- −3.14M
- −43.3% vs. previous
- Days to cover
- 4.63
- At average daily volume
Superinvestors holding ABVX, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding ABVX at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Abivax S.A. insiders from Form 4, newest first.
No open-market purchases or sales by Abivax S.A. insiders are on file.
Top 10 13F holders, Q3 2026
See all 318 holdersThe largest institutional positions in Abivax S.A. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Helikon Investments Ltd | 4,222,896 | $418.2M | 11.88% | +1,435,765+51.5% | Added |
| Darwin Global Management, Ltd. | 4,021,583 | $398.2M | 9.98% | +400,000+11.0% | Added |
| Vestal Point Capital, LP | 3,960,000 | $392.1M | 10.13% | +1,610,557+68.6% | Added |
| TCG Crossover Management, LLC | 3,663,038 | $362.7M | 10.25% | −2,344,796−39.0% | Reduced |
| Janus Henderson Group PLC | 2,147,116 | $212.6M | 0.09% | +2,147,116 | New |
| ADAR1 Capital Management, LLC | 2,050,822 | $203.1M | 8.71% | +246,119+13.6% | Added |
| Westfield Capital Management Co LP | 1,651,819 | $163.6M | 0.54% | +341,994+26.1% | Added |
| Caligan Partners LP | 1,557,924 | $154.3M | 9.44% | 00.0% | Unchanged |
| Morgan Stanley | 1,437,880 | $142.4M | 0.01% | +5,695+0.4% | Added |
| Citadel Advisors LLC | 1,308,467 | $129.6M | 0.07% | −129,885−9.0% | Reduced |
Holders of 5% or more of ABVX
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Abivax S.A..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Invus Global Management, LLC | 13G/A | 6.00%4.83M shares | +1.00 ppfrom 5.00% | Apr 11, 20253 filings | Aug 13, 2026 | SEC |